Completed PHASE1 INTERVENTIONAL 1-arm NCT00720174

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma

Sponsor: National Cancer Institute (NCI)

Conditions Adult Angiosarcoma Adult Desmoplastic Small Round Cell Tumor Adult Epithelioid Sarcoma Adult Extraskeletal Myxoid Chondrosarcoma Adult Extraskeletal Osteosarcoma Adult Fibrosarcoma Adult Leiomyosarcoma Adult Liposarcoma Adult Malignant Mesenchymoma Adult Malignant Peripheral Nerve Sheath Tumor Adult Rhabdomyosarcoma Adult Synovial Sarcoma Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone Childhood Angiosarcoma Childhood Desmoplastic Small Round Cell Tumor Childhood Epithelioid Sarcoma Childhood Fibrosarcoma Childhood Leiomyosarcoma Childhood Liposarcoma Childhood Malignant Mesenchymoma Childhood Malignant Peripheral Nerve Sheath Tumor Childhood Pleomorphic Rhabdomyosarcoma Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features Childhood Synovial Sarcoma Dermatofibrosarcoma Protuberans Malignant Adult Hemangiopericytoma Malignant Childhood Hemangiopericytoma Metastatic Childhood Soft Tissue Sarcoma Previously Treated Childhood Rhabdomyosarcoma Recurrent Adult Soft Tissue Sarcoma Recurrent Childhood Rhabdomyosarcoma Recurrent Childhood Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma Untreated Childhood Rhabdomyosarcoma

Interventions Cixutumumab Doxorubicin Hydrochloride Laboratory Biomarker Analysis

Updated 7 times since 2017 Last updated: May 16, 2016 Started: Jun 30, 2008 Primary completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Adult Angiosarcoma and Adult Desmoplastic Small Round Cell Tumor and is currently completed. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Chicago, United States , Decatur, United States , Evanston, United States , Fort Wayne, United States , Harvey, United States , Joliet, United States , Maywood, United States , Milwaukee, United States and 3 more locations